Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Blog - Page 72

Blog

Chinese healers created the first antibiotic to treat boils
Biotechnology | Life Science History | Medicine | Prehistory

Chinese healers created the first antibiotic to treat boils

Around 600 BCE, Chinese healers created the first antibiotic – moldy soybean curds – to treat boils.

Read More Chinese healers created the first antibiotic to treat boilsContinue

Hippocrates described mumps, diphtheria, epidemic jaundice, and other conditions
Biotechnology | Disease | Life Science History | Prehistory

Hippocrates described mumps, diphtheria, epidemic jaundice, and other conditions

Around 500 BCE, Hippocrates, a pioneering physician in the history of Medicine, and considered as the principal author…

Read More Hippocrates described mumps, diphtheria, epidemic jaundice, and other conditionsContinue

Chinese growers used powdered chrysanthemum (pyrethrins) as the first insecticide
Agriculture | Biotechnology | Life Science History | Prehistory

Chinese growers used powdered chrysanthemum (pyrethrins) as the first insecticide

Around 100 BCE, Chinese growers used powdered chrysanthemum (pyrethrins) as the first insecticide.

Read More Chinese growers used powdered chrysanthemum (pyrethrins) as the first insecticideContinue

Animal Biosecurity and Agro-Defense Program launched at Auburn
Life Science History | USDA | Veterinary

Animal Biosecurity and Agro-Defense Program launched at Auburn

On Oct. 2, 2021, the Auburn University College of Veterinary Medicine was announced as the home to the…

Read More Animal Biosecurity and Agro-Defense Program launched at AuburnContinue

Merck and Ridgeback’s oral antiviral reduced risk of hospitalization or death for patients with COVID-19 in positive phase 3 study
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics

Merck and Ridgeback’s oral antiviral reduced risk of hospitalization or death for patients with COVID-19 in positive phase 3 study

On Oct. 1, 2021, Merck and Ridgeback Biotherapeutics announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine,…

Read More Merck and Ridgeback’s oral antiviral reduced risk of hospitalization or death for patients with COVID-19 in positive phase 3 studyContinue

Humanigen submitted all planned modules forpotential conditional Marketing Authorization from UKメs MHRA
COVID-19 | Life Science History

Humanigen submitted all planned modules forpotential conditional Marketing Authorization from UKメs MHRA

On Oct. 1, 2021, Humanigen announced it had submitted all the planned modules as well as a risk…

Read More Humanigen submitted all planned modules forpotential conditional Marketing Authorization from UKメs MHRAContinue

Labcorp received EUA for at home collection kit for combined COVID-19 and flu detection
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza

Labcorp received EUA for at home collection kit for combined COVID-19 and flu detection

On Oct. 1, 2021, LabCorp announced that it had received Emergency Use Authorization (EUA) from the U.S. Food…

Read More Labcorp received EUA for at home collection kit for combined COVID-19 and flu detectionContinue

FDA approved Kiteメs Tecartusᆴ as first and only Car T for adults with Relapsed or Refractory B-cell ALL
FDA | Life Science History

FDA approved Kiteメs Tecartusᆴ as first and only Car T for adults with Relapsed or Refractory B-cell ALL

On Oct. 1, 2021, Kite, a Gilead Company, announced the U.S. Food and Drug Administration had granted approval…

Read More FDA approved Kiteメs Tecartusᆴ as first and only Car T for adults with Relapsed or Refractory B-cell ALLContinue

Relief reported that collaboration partner announced a second favorable safety report for ZYESAMI(TM) in Patients with COVID-19
COVID-19 | Life Science History

Relief reported that collaboration partner announced a second favorable safety report for ZYESAMI(TM) in Patients with COVID-19

On Sept. 30, 2021, RELIEF THERAPEUTICS reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals,…

Read More Relief reported that collaboration partner announced a second favorable safety report for ZYESAMI(TM) in Patients with COVID-19Continue

Fifteen African countries hit 10% COVID-19 vaccination goal
COVID-19 | Vaccine | WHO

Fifteen African countries hit 10% COVID-19 vaccination goal

On Sept. 30, 2021, the WHO announced that fifteen African countries – nearly a third of the continent’s…

Read More Fifteen African countries hit 10% COVID-19 vaccination goalContinue

Trevena announced results of TRV027 proof-of-concept study in COVID-19 patients
COVID-19 | Life Science History

Trevena announced results of TRV027 proof-of-concept study in COVID-19 patients

On Sept. 30, 2021, Trevena announced data from 30 patients enrolled in the proof-of-concept study of TRV027, the…

Read More Trevena announced results of TRV027 proof-of-concept study in COVID-19 patientsContinue

U.S. FDA cleared Naeotom Alpha, worldメs first photon-counting computer tomograph
FDA | Life Science History

U.S. FDA cleared Naeotom Alpha, worldメs first photon-counting computer tomograph

On Sept. 30 2021, Siemens Healthineers announced the Food and Drug Administration (FDA) 510 (k) clearance of the…

Read More U.S. FDA cleared Naeotom Alpha, worldメs first photon-counting computer tomographContinue

COVID-19 vaccinated vs. non-vaccinated
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Medical Device | Neurology | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine

COVID-19 vaccinated vs. non-vaccinated

This cartoon illustrates the various issues facing individuals across the U.S. who are vaccinated against COVID-19 verus those…

Read More COVID-19 vaccinated vs. non-vaccinatedContinue

Colossal, a de-extinction company was founded to bring the Woolly Mammoth back to life
Life Science History

Colossal, a de-extinction company was founded to bring the Woolly Mammoth back to life

On Sept. 29, 2021, Colossal, a de-extinction company that is combining the science of genetics with the business…

Read More Colossal, a de-extinction company was founded to bring the Woolly Mammoth back to lifeContinue

Pfizer reported positive top-line results of phase 3 study exploring coadministration of Prevnar 20 With seasonal Flu vaccine
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics

Pfizer reported positive top-line results of phase 3 study exploring coadministration of Prevnar 20 With seasonal Flu vaccine

On Sept. 29, 2021, Pfizer and BioNTech announced they had submitted data to the U.S. Food and Drug…

Read More Pfizer reported positive top-line results of phase 3 study exploring coadministration of Prevnar 20 With seasonal Flu vaccineContinue

NEJM published positive phase 3 trial resulted for REGEN-COV (casirivimab and imdevimab) to treat COVID-19
Biotechnology | COVID-19 | Therapeutics

NEJM published positive phase 3 trial resulted for REGEN-COV (casirivimab and imdevimab) to treat COVID-19

On Sept. 29, 2021, Regeneron announced that the New England Journal of Medicine (NEJM) published positive detailed results…

Read More NEJM published positive phase 3 trial resulted for REGEN-COV (casirivimab and imdevimab) to treat COVID-19Continue

VBI Vaccines announced preclinical data and Initiation of VBI-2905 clinical trial targeting broadened immunity against COVID-19
COVID-19 | Life Science History | Vaccine

VBI Vaccines announced preclinical data and Initiation of VBI-2905 clinical trial targeting broadened immunity against COVID-19

On Sept. 29, 2021, VBI Vaccines announced positive results from multiple preclinical studies against several COVID-19 variants of…

Read More VBI Vaccines announced preclinical data and Initiation of VBI-2905 clinical trial targeting broadened immunity against COVID-19Continue

Phase II/III trial showed Ronapreve (casirivimab and imdevimab) significantly reduced viral load in patients hospitalised with COVID-19
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

Phase II/III trial showed Ronapreve (casirivimab and imdevimab) significantly reduced viral load in patients hospitalised with COVID-19

On Sept. 29, 2021, Roche confirmed positive data from the phase II/III 2066 study, investigating Ronapreveル (casirivimab and…

Read More Phase II/III trial showed Ronapreve (casirivimab and imdevimab) significantly reduced viral load in patients hospitalised with COVID-19Continue

2022 Breakthrough Prize in Life Sciences awarded to Penn Medicine mRNA pioneers Drew Weissman and Katalin Karik
Biotechnology | COVID-19 | Therapeutics | Vaccine

2022 Breakthrough Prize in Life Sciences awarded to Penn Medicine mRNA pioneers Drew Weissman and Katalin Karik

On Sept. 29, 2021, the University of Pennsylvania announced that the Breakthrough Prize in Life Sciences was awarded…

Read More 2022 Breakthrough Prize in Life Sciences awarded to Penn Medicine mRNA pioneers Drew Weissman and Katalin KarikContinue

Cepheid received Emergency Use Authorization For SARS-CoV-2, Flu A, Flu B and RSV combination test
COVID-19 | Life Science History

Cepheid received Emergency Use Authorization For SARS-CoV-2, Flu A, Flu B and RSV combination test

On Sept. 29, 2021, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…

Read More Cepheid received Emergency Use Authorization For SARS-CoV-2, Flu A, Flu B and RSV combination testContinue

NIAID issued new awards to fund ‘pan-coronavirus’ vaccines
Biotechnology | Vaccine

NIAID issued new awards to fund ‘pan-coronavirus’ vaccines

On Sept. 28, 2021, the National Institute of Allergy and Infectious Diseases announced it had awarded approximately $36.3…

Read More NIAID issued new awards to fund ‘pan-coronavirus’ vaccinesContinue

Sanofi terminated mRNA COVID-19 vaccine development to focus on recombinant vaccine candidate
Biotechnology | COVID-19 | Infectious Disease | Pharmaceutical | Vaccine

Sanofi terminated mRNA COVID-19 vaccine development to focus on recombinant vaccine candidate

On Sept. 28, 2021, Sanofi announced that it had terminated plans for its own mRNA-based COVID-19 vaccine given…

Read More Sanofi terminated mRNA COVID-19 vaccine development to focus on recombinant vaccine candidateContinue

TGen part of $60 million grant awarded to UArizona to create national Precision Aging Network
Life Science History

TGen part of $60 million grant awarded to UArizona to create national Precision Aging Network

On Sept. 28, 2021, TGen, an affiliate of City of Hope, will use its MindCrowd website portal to…

Read More TGen part of $60 million grant awarded to UArizona to create national Precision Aging NetworkContinue

AIM ImmunoTech submitted pre-IND application to FDA for phase 2 clinical studies of Ampligen as potential therapeutic for COVID-19
COVID-19 | Life Science History

AIM ImmunoTech submitted pre-IND application to FDA for phase 2 clinical studies of Ampligen as potential therapeutic for COVID-19

On Sept. 28, 2021, AIM ImmunoTech announced that is had submitted a Pre-Investigational New Drug application (Pre-IND) to…

Read More AIM ImmunoTech submitted pre-IND application to FDA for phase 2 clinical studies of Ampligen as potential therapeutic for COVID-19Continue

University of Missouri researchers identified mutations of Delta, Delta Plus variants
COVID-19 | Life Science History

University of Missouri researchers identified mutations of Delta, Delta Plus variants

On Sept. 28, 2021, the University of Missouri researcher Kamlendra Singh led a team that analyzed protein sequences…

Read More University of Missouri researchers identified mutations of Delta, Delta Plus variantsContinue

Over half of U.S. children have detectable levels of lead in their blood in Quest Diagnostics study published in JAMA
Life Science History

Over half of U.S. children have detectable levels of lead in their blood in Quest Diagnostics study published in JAMA

On Sept. 28, 2021, Quest Diagnostics reported that one in two (50.5%) American children under six years of…

Read More Over half of U.S. children have detectable levels of lead in their blood in Quest Diagnostics study published in JAMAContinue

Soligenix announced publication demonstrating efficacy and broad neutralizing activity of its COVID-19 Vaccine
Biotechnology | COVID-19 | Life Science History | Therapeutics | Vaccine

Soligenix announced publication demonstrating efficacy and broad neutralizing activity of its COVID-19 Vaccine

On Sept. 28, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVax (heat stable COVID-19 vaccine program)…

Read More Soligenix announced publication demonstrating efficacy and broad neutralizing activity of its COVID-19 VaccineContinue

Pfizer and BioNTech submitted initial data to FDA from pivotal trial of COVID-19 vaccine in children 5 to
COVID-19 | FDA | Life Science History

Pfizer and BioNTech submitted initial data to FDA from pivotal trial of COVID-19 vaccine in children 5 to <12 years of age

On Sept. 28, 2021, Pfizer and BioNTech announced they had submitted data to the U.S. Food and Drug…

Read More Pfizer and BioNTech submitted initial data to FDA from pivotal trial of COVID-19 vaccine in children 5 to <12 years of ageContinue

Relief reported that collaboration partner announced improved survival in highly comorbid COVID-19 patients treated with ZYESAMITM
COVID-19 | Life Science History

Relief reported that collaboration partner announced improved survival in highly comorbid COVID-19 patients treated with ZYESAMITM

On Sept. 27, 2021, RELIEF THERAPEUTICS reported its U.S. collaboration partner, NRx Pharmaceuticals, had announced top line data…

Read More Relief reported that collaboration partner announced improved survival in highly comorbid COVID-19 patients treated with ZYESAMITMContinue

Pfizer started global phase 2/3 EPIC-PEP study of novel COVID-19 oral antiviral candidate for post-exposure prophylaxis in adults
COVID-19 | Life Science History

Pfizer started global phase 2/3 EPIC-PEP study of novel COVID-19 oral antiviral candidate for post-exposure prophylaxis in adults

On Sept. 27, 2021, Pfizer announced the start of the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for…

Read More Pfizer started global phase 2/3 EPIC-PEP study of novel COVID-19 oral antiviral candidate for post-exposure prophylaxis in adultsContinue

Page navigation

Previous PagePrevious 1 … 70 71 72 73 74 … 343 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search